Phone Toll Free Number: (800) 777-8189
Phone Toll Free Number: (800) 777-8189
Spondylitis Plus Archive
Share:
BySpondylitis Association of America

SAA Turns 35! How Did We Get Here?

35 years ago, a small group of AS patients changed the course of spondyloarthritis, and jump-started its research…

Read more
BySpondylitis Association of America

Highlights From SAA’s Spondylitis Seminar: Q&A With Dr. John Reveille

Editor’s Note: On November 4, 2017 the Spondylitis…

Read more
BySpondylitis Association of America

Non-Medicinal Approaches To Treating Spondyloarthritis

In recent years, experts in patient care in spondyloarthritis have recognized that a hands on, multi-use approach that…

Read more
BySpondylitis Association of America

Fatigue in Spondyloarthritis: Identifying and Addressing Causes

While fatigue is not unique to spondyloarthritis, it is a rather common symptom of it, and one that…

Read more
ByLianne Gensler

Q&A With A Medical Professional

Question: We hear so much about customized medicine in the media. We know they can test for whether a mood altering drug, such as...

Read more
ByRichard Feingold

Clarifying the Social Security Disability Program

This article will explain and simplify the Social Security disability program and how it generally applies to claims related to spondyloarthritis.

Read more
ByKathy Holliman

Sex Differences in Ankylosing Spondylitis

“It is evident that sex plays a very important role in AS. The symptomatic burden of AS tends to be higher in females than in…

Read more
BySpondylitis Association of America

A Prescription for Exercise

With all the current therapies for ankylosing spondylitis (AS)—anti-inflammatory medications, biologics, dietary modifications, and even surgery in some cases— the consensus among most is that…

Read more
BySpondylitis Association of America

Biosimilars

The biologic drug landscape shifted in March 2015 when The Food and Drug Administration approved the first of a new subclass of treatments to be marketed in the United States—biosimilars.  Recently, a second biosimilar product—Inflectra (infliximab-dyyb)—a biologic…

Read more
1 2 3 4 5